4 Forces Compressing Hospital Profit Margins in 2026
Hospital profit margins are compressing again in 2026, and the brief recovery health systems posted in 2024 did not hold. The median operating margin across U.S. health systems ran -0.1% in 2023, recovered to 1.6% in 2024, slid to 1.0% in 2025, and has fallen to a 0.4% year-to-date median as of March 2026.
The cause is structural, not seasonal: input costs are rising faster than reimbursement, government payers are paying below cost, Medicare Advantage friction is eroding collections, and a coverage cliff is pushing more patients into self-pay and uncompensated care.
For commercial leaders selling into health systems, this is the backdrop behind every budget conversation this year. Understanding why margins are under pressure is what separates a credible executive conversation from a pitch that misses. This references recent research and analysis from The Health Management Academy to break down the four forces driving the squeeze and what each one changes about how health system leaders buy.
A recovery that didn’t hold
Health system financial performance looked like it had turned a corner in 2024. Median operating margins climbed to 1.6% after a negative 2023. That improvement was short-lived. In 2025, revenue and expense growth converged at 8.4%, erasing the tailwind that had briefly widened margins. The median operating margin fell to 1.0% for the year and kept sliding into 2026.
These are thin margins by any standard, and they vary widely.
Larger health systems with more diversified revenue tend to hold positive margins more consistently than smaller systems, where a single bad quarter can erase a year of gains. The pattern matters because it sets the spending posture for the entire organization: when the median system is operating near breakeven, every technology and services decision gets measured against its effect on the margin.
Force 1: Input Costs Are Outrunning Reimbursement
The cost side of the ledger is rising faster than the revenue side, and it has been since the pandemic reset the labor market. For hospitals in 2025, workforce costs rose 5.6%, supply costs rose 9.9%, and drug costs rose 13.6%. Pharmaceutical inflation is the sharpest pressure inside the supply line.
Labor costs: Wage pressure has persisted across clinical and non-clinical roles. The COVID-19 era spike in contract labor has eased, but it has not disappeared, and labor shortages continue to keep base wages elevated.
Supply costs: Up roughly 10%, driven heavily by drug prices. This is a top-of-mind concern for supply chain and pharmacy leaders.
Purchased services: Up 7.7% in 2025, adding further strain to operating budgets that have little room to absorb it.
The problem is the gap. Reimbursement increases are not keeping pace with any of these cost lines, so each year of growth in hospital expenses translates directly into margin erosion. This is why operating expenses, not revenue shortfalls, are the dominant story in most health system finance reviews right now.
Force 2: Government Underpayment
Medicare and Medicaid pay below the cost of delivering care, and the gap is widening. In 2024, Medicare paid just 83 cents for every dollar of hospital cost, more than $100 billion in annual underpayments, according to the American Hospital Association. Because government payers cover such a large share of patient care volume, that shortfall flows straight to the bottom line.
The federal outlook signals more of the same. The 2027 proposed inpatient rate is +2.4%, down 0.2 points from 2026, and CMS has proposed a $564 million decrease in disproportionate share and uncompensated care payments.
Mandatory value-based payment models are arriving on top of that. TEAM went live January 1, 2026, for acute care hospitals, the Ambulatory Specialty Model launches in 2027, and a proposed nationwide joint-replacement model would follow in late 2027, the first nationwide mandatory episode-based payment model in Medicare history. Most health systems lack the episode-risk infrastructure these models assume.
Force 3: Medicare Advantage Friction
Medicare Advantage plans received a 2027 rate bump, but the structural pressure that erodes provider margins has not eased. Payers processed 53 million prior authorization determinations in 2024, 1.7 per enrollee. When providers appeal denials, 81% are overturned, which suggests most were not clinically warranted in the first place. Each denial and appeal carries administrative costs and delays collections.
A health system CFO put the economics plainly: Medicare Advantage is “at best, a 2% to 3% margin business.” The proposed CMS Star Ratings overhaul could make it worse by removing accountability metrics tied to appeals timeliness and outcomes - the measures that pressured plans toward fairer behavior.
Force 4: The Coverage Cliff
The fourth force hits the revenue side through patient mix. Two policy changes are converging to push millions of people out of coverage and into self-pay.
Medicaid work requirements are projected to cause 3 to 7 million enrollment losses by 2028, with the Congressional Budget Office estimating 5.2 million will lose coverage by 2034 from work requirements alone. Nebraska is an early test case, with roughly 25,000 expected to lose coverage.
At the same time, the enhanced ACA premium tax credits expired at the end of 2025. Average out-of-pocket premiums rose 58%, from $113 to $178 per month, and marketplace enrollment fell by 1.2 million for 2026, the first decline since the enhanced subsidies took effect.
For health systems, fewer covered patients means more uncompensated care costs and more bad debt. Sustained over time, that pressure contributes to service-line cuts, reduced capacity in vulnerable communities, and the financial strain that drives consolidation among systems unable to operate independently. The institutions most exposed are often those serving the communities with the least ability to absorb a coverage loss.
What the Squeeze Changes for Industry Partners
Four forces, one result: health system leaders are buying differently.
When margins sit near breakeven, the question turns from whether a solution is innovative to whether it protects or improves the margin, and how fast.
That reshapes the commercial conversation in a few concrete ways. Solutions that tie directly to cost reduction, denial recovery, or charity-care and financial-counseling workflows are getting attention because they map onto the exact pressures above. Decision authority is also consolidating: technology leaders report doing less delegation and more direct involvement, and CIO sign-off is now triggered by smaller contracts and shorter terms. The room you need to be in is higher up than it used to be.
Health Systems’ Ask of Industry Partners
The clearest signal comes from the executives themselves. Asked what they wish industry partners did better, technology leaders did not ask for better products. They asked partners to prove ROI rather than tout features, integrate into existing workflows, price transparently, understand the organization, and stay engaged after implementation.
As one leader put it: “We don’t buy tech, we buy solutions.”
Know the buyer before you are in the room. The Health Management Academy’s Executive Convening conferences are one way to achieve this in order to hear first-hand, one-to-one, each leader’s priorities, pressures, and what they want from partners.
Get the full research
This article covers the margin story. The full Q2 2026 research brief and on-demand webinar go further into the three mandatory CMS payment models, the GLP-1 cost squeeze, where technology budgets are actually moving, and how AI investment differs by health system size.
Download the research brief and watch the webinar replay: 2026 Trends in Healthcare for Industry Executives.